Costs and persistence of alpha-2 adrenergic agonists versus carbonic anhydrase inhibitors, both associated with prostaglandin analogues, for glaucoma as recorded by The United Kingdom General Practitioner Research Database

Philippe Denis¹
Antoine Lafuma²
Gilles Berdeaux³

¹Hôpital Edouard Herriot, Lyon, France; ²Cemka, Bourg-la-Reine, France; ³Alcon France, Rueil-Malmaison, France

Abstract: The persistence and costs of carbonic anhydrase inhibitors + prostaglandin analogues (CAIs + PGAs) vs alpha-2 adrenergic agonists + prostaglandin analogues (alpha-2 agonists + PGAs) were compared, based on The United Kingdom General Practitioner Research Database. Patients with a diagnosis of ocular hypertension, glaucoma, or treated for this, were selected. Selected patients were prescribed CAIs + PGAs or alpha-2 agonists + PGAs. Treatment failure was defined as a prescription change (adding, removing, or replacing glaucoma treatment, or initiating laser or surgery). Times to treatment failure were compared with a Cox model adjusted by a propensity score. Mean patient age was 69.0 years and 47.6% were males. Treatment failure at 1 year was experienced by 58.8% receiving CAIs + PGAs and 66.0% of patients receiving alpha-2 agonists + PGAs (p < 0.001). The hazard ratio for failure was 0.82 (p < 0.001) in favor of CAIs + PGAs after adjusting on age, gender, comorbidities, and duration of follow-up. Adjusted annual costs of glaucoma management did not differ significantly between treatments, £440.63 with alpha-2 agonists + PGAs and £413.37 with CAIs + PGAs. CAIs + PGAs therapies appear more persistent than alpha-2 agonist + PGA in everyday clinical practice, at a similar cost.

Keywords: glaucoma, alpha-2 adrenergic agonists, carbonic anhydrase inhibitor, prostaglandin, effectiveness economics, costs

Introduction
Glaucoma in various forms occurs in about 2% of the population aged more than 40 years (Weih et al 2001). It affects children and young adults far less frequently than the elderly. It is estimated that in England and Wales, alone, more than 500,000 people suffer from glaucoma and more than 70 million people are affected worldwide (Broman and Quigley 2006) while uncorrected refractive errors remained the major cause of visual impairment (Resnikoff et al 2004). In the great majority of cases the condition takes a chronic, slowly developing course (primary open angle glaucoma: POAG). Studies have demonstrated that about half of all POAG cases remain undiagnosed in the Western developed countries. The risk of POAG is about four times greater for Afro-American people than for Caucasians.

POAG usually affects both eyes and initially produces few symptoms. Eventually, untreated patients may become aware of severely restricted visual fields, or even a loss of central vision in the worst eye. Although blindness from glaucoma is uncommon, it is wholly or partially the third reason to register on the blind register for England

Correspondence: Gilles Berdeaux
Alcon France, 4, Rue Henri Sainte-Claire Deville, F-92563 Rueil-Malmaison cedex France
Tel +33 1 4710 4860
Fax +33 1 4710 2770
Email gilles.berdeaux@alconlabs.com
and Wales, and is the leading cause of preventable blindness in the UK (Bunce and Wormald 2006). When treated, the probability of glaucoma-related blindness, after treatment of both eyes, was estimated at 9% at 20 years after diagnosis (Hattenhauer et al 1998). A significant risk factor for glaucoma blindness is advanced loss of vision when the condition is first detected. Appropriate examinations during routine eye tests are therefore essential to detect glaucoma early and prevent significant sight loss.

The annual economic burden of glaucoma in the UK was estimated at £62 million in direct medical costs in 1994 (Coyle and Drummond 1995). Total annual UK costs of glaucoma, including direct, indirect and social cost estimated for the Blind Association ‘Guide Dog’ service reached £27 billion (Guide Dog for the Blind Association).

Observational data show that frequent medication changes increase the costs of glaucoma treatment (Kobelt et al 1998; Denis et al 2004). Although the daily cost of a drug must be considered when prescribing (Jönsson and Krieglstein 1998; Fiscella et al 1999; Vold et al 2002; Rylander and Vold 2008), the impact of efficacy should not be overlooked as this can diminish the need for other medical resources, such as ophthalmologist visits, surgery, or laser therapy (Kooner and Zimmerman 1987).

Increased intraocular pressure (IOP) is the main risk factor whereas the other causes of glaucomatous optic neuropathy remain unknown. Various strategies in current use decrease IOP and so lower the risk of glaucoma, thereby limiting its development (Kass et al 2002) and controlling progression (Heijl et al 2002; Leske et al 2003; The AGIS investigators 2004; EGPS 2005). Surgery, laser therapy and several classes of pharmacological agents in common use have been introduced in recent decades. Medications include beta-blockers (marketed in the late 1970s), carbonic anhydrase inhibitors (CIAs) in the mid-1990s, and both alpha-2 adrenergic agonists and prostaglandin analogues (PGAs) in the late 1990s. It is an accepted practice to start treatment with a single drug, followed by drug combinations (whether, or not, fixed) after an initial failure. A second-line monotherapy may be also used in case of failure of the first line monotherapy. Randomized clinical trials of brimonidine vs brinzolamide both associated with travoprost showed a better IOP control in the patients treated with travoprost and brinzolamide (Reis et al 2006; Feldman et al 2007).

Health authorities increasingly demand documentation showing drug efficacy based on prescriptions in everyday practice (Hjelmgren et al 2001). Retrospective cohort studies comparing treatments can be effective strategies to provide such information. Studies using the endpoint of ‘persistence’ or ‘adherence’ to treatment are now being applied to glaucoma treatment (Deschaseaux-Voinet et al 2003; Nordstrom et al 2005; Covert and Robin 2006; Wilensky et al 2006).

An extensive source of patient data is The United Kingdom General Practitioner Research Database (UK-GPRD) which collects information from a representative sample of general practitioners (GPs) (http://www.gprd.com/home/). Glaucoma data, for example, are collected comprehensively because GPs perform a gatekeeper role in the UK. This paper compares the costs and effectiveness of two medications (alpha-2 adrenergic agonists vs carbonic anhydrase inhibitors) each used in combination with a prostaglandin analogue as glaucoma therapy.

Materials and methods

Data sources

This study extracted data from the UK-GPRD, which is the world’s largest computerized database with anonymous longitudinal records of approximately three million patients in primary medical care collected continuously by general practitioners since 1987. Records include demographic information (other than race) on age, gender, medical diagnosis, prescriptions, clinical events, and hospital referrals.

Data management

The UK-GPRD mainly reports incidences (eg, visits, drugs, comorbidities), hence considerable data management must be performed to extrapolate the prevalence of events.

Treatments are, here, represented by product names and dates of prescription. The main assumption was that carbonic anhydrase inhibitors (CAIs) or alpha-2 agonists were prescribed for a maximum period of 100 days which approximately corresponds to three eye-drop bottles. Initial prescriptions rarely exceeded this quantity. Two consecutive prescriptions for less than 100 days each were presumed to represent renewed therapy. Any other ophthalmic product prescribed during the same period was regarded as an additional treatment.

Patient selection and inclusion

Three sets of terms were used to identify the UK-GPRD population of patients treated for glaucoma or intra-ocular hypertension, as follows: (1) Diagnosis required specific ‘open-angle’ and more generic ‘glaucoma’ terms that excluded specifically ‘closed-angle’, ‘angle closure’ and ‘glaucoma due to other causes’ (eg, trauma); (2) Surgery or laser terms for glaucoma were flagged as specific
All tests were interpreted two-sided with either a CAI+PGA or an alpha-2 agonist+PGA, and (3) follow-up longer than 6 months once the study therapies were begun. Patients with pre-existing CAI or alpha-2 agonist treatments were excluded.

**Evaluation criteria**

Treatment failure was defined as a prescription change replacing or discontinuing the initial medication, or adding a new medication (association). Patients given laser therapy or surgery for glaucoma were regarded as treatment failures.

**Statistical methods**

Statistical analyses used SAS V9.1 software (SAS Institute; North Carolina, USA). Treatment groups were compared at baseline on demography, general comorbidities and eye comorbidities. Continuous variables were compared by a t-test after verifying normality or by a non-parametric Wilcoxon test, in the absence of normality. Discontinuous variables were analyzed by a Chi-square test that was replaced by Fisher’s exact permutation test when samples were small. All tests were interpreted two-sided with \( \alpha = 0.05 \).

Survival curves by treatment group were estimated using the Kaplan-Meier method, without adjustment. The treatment failure hazard-ratio between alpha-2 agonist and CAI was estimated by a Cox regression, with and without adjustment.

**Economic evaluation**

Direct and consequential costs of glaucoma medical care were analyzed from the economic perspective of the UK National Health Service.

The UK-GPRD yielded the following glaucoma information: (1) laser therapy and surgery, (2) hospitalizations for glaucoma, (3) glaucoma medication, (4) visits to GPs and glaucoma specialists, and (5) prescription renewals by telephone. Consumption items were collected for each patient from the prescription to the final follow-up day and included treatment subsequent to medication failure.

Unit costs of medication were taken from the British National Formulary (2005) (www.bnf.com) and did not include drug discounts. Unit costs for medical procedures (surgery, laser therapy, hospitalization, and consultations) were taken from Jönsson and Krieglstein (1998) and inflated to the year 2005 by applying the National Health Service inflation rate (Statistics of OECD). Visits to ophthalmologists were costed at £107 per patient hour and follow-up visits were assumed to last 15 minutes (Curtis and Netten A 2005). General practitioner visits were costed at £129 per patient hour and follow-up visits were assumed to last 15 minutes (Curtis and Netten 2005). We estimated both the total and annual costs of each treatment regimen.

**Results**

In total, 54,513 glaucoma patients were selected from the UK-GPRD representing all UK regions. A subgroup of 6,176 patients met our study criteria, comprising 4,792 treated with CAIs + PGAs and 1,384 with alpha-2 agonists + PGAs. The 3:1 ratio CAIs/alpha-2 agonists showed that CAIs + PGAs were prescribed more frequently for glaucoma than alpha-2 agonists + PGAs.
No statistically significant differences in gender distribution (47.6%) or age (mean 69.0 years) were found at inclusion between patients treated with CAIs or alpha-2 agonists (Table 1). However, time since diagnosis was significantly \( (p < 0.001) \) longer for the CAI group, whereas the mean duration of follow-up was significantly \( (p < 0.001) \) longer for alpha-2 agonist group (1,060 days) than the CAI group (838 days).

General health and eye comorbidity data, comprising all prevalent and incident events from entry into the UK-GPRD to the exit date of the present study, are presented in Table 2. Statistically significant differences were noted between the two treatment groups. As compared to CAIs, patients treated with alpha-2 agonists experienced more ocular sensory symptoms and general comorbidities, ie, cardiac disorders, immune system disorders, nervous system disorders, psychiatric disorders, and respiratory disorders. Neither category of comorbidities was associated with time to treatment failure.

One year after starting glaucoma medication, patients experienced less treatment failure with CAIs than with alpha-2 agonists (Table 3) and this advantage was maintained throughout the subsequent 3 years. Accordingly, the hazard ratio for failure was significantly less with CAIs \( (OR = 0.82; \ p < 0.0001) \) before adjustment and remained so after adjustment for age, gender, comorbidities, and duration of follow-up \( (OR = 0.82; \ p < 0.001) \). Time to 50% failure was longer with CAIs (8.5 months). Survival curves are shown in Figure 1.

Most of the patients were followed up until failure of the current treatment-line: both treatments failed for 5,734 of 6,176 patients (92.8%) during the study period (Table 4). Second-line treatment for more than half of all patients was a switch to prostaglandin analogues (in monotherapy or in combination, with beta-blockers the next preference) and for 2.9% a switch to surgery or laser therapy.

Average monthly costs associated with CAIs + PGAs were estimated at £33.98 per patient and were close to those of alpha-2 agonists + PGAs, £36.22 (Table 5). There was no significant difference between these costs even after adjustment. Average daily costs with CAIs were 98.2% of those with alpha-2 agonists. The adjusted annual cost difference of a patient receiving CAI treatment was only £27.26 less than for an alpha-2 agonist.

**Discussion**

The use of carbonic anhydrase inhibitors and prostaglandin analogues was compared in this study with alpha-2 adrenergic agonists and prostaglandin analogues during everyday UK general practice.

Many researchers claim that non-randomized studies lead to unreliable results and advocate the unique use of randomized controlled trials (RCTs) (Dunn et al 2002). Despite the risk of producing biased treatment estimates, other authors favor the use of non-randomized studies on the basis that these can lead to results which may be compared with those reported in RCTs (Concato et al 2000). Therefore, sources of existing observational data can provide valuable information. Also, RCTs are generally conducted under strict protocol conditions that differ from everyday practice. Consequently, some authors assert that randomized studies do not provide information of much relevance to decision-makers (Heckman et al 1995). Thus, while most clinical researchers regard observational studies as exploratory tools yielding results that need to be confirmed by RCTs, non-randomized studies need to be performed after RCTs to assess the external validity of RCT findings. Our database analysis should be interpreted in this manner.

On the information available, we observed no socio-demographic differences between patients receiving CAIs or alpha-2 agonists, except for time since diagnosis and duration of follow-up, despite the lack of treatment randomization. The latter is explained by the earlier Market Access Authorization of brimonidine (European Medicines Agency). General and ocular comorbidity differences between the treatment groups were not related to clinical outcomes and no adjustment was necessary. Nonetheless, we analyzed treatment failure both with and without adjustment and obtained very similar results, confirming the robustness of our findings. In addition, we used a propensity score analysis which is well accepted by health authorities (Yue 2004). This approach follows the recommendations issued by the British Medical Journal (Mamdani et al 2005; Normand et al 2005; Rochon et al 2005).
As far as possible, taking into account the information available in the UK GPRD database, we gave due attention to controlling selection bias and confounding factors. First, these matters are clinically relevant as both drug classes had the same indications. Moreover, the choice between a CAI, or an alpha-2 agonist combined with a PGA, after the latter monotherapy has failed, is clinically important. Second, data were collected on available factors known to be confounded with treatment persistence, eg, age as a surrogate endpoint of glaucoma severity, eye, and general co-morbidities. Data on other confounding factors were not recorded in the database (eg, race and IOP at treatment initiation). However, as the estimated propensity score may be regarded as a latent variable, summarizing disease severity, the reported findings were duly adjusted. Third, baseline comparison was performed and showed no major differences between the treatment groups. Fourth, none of the few unbalanced variables was linked to treatment persistence. Hence, our propensity score might have led to some over-adjustment, despite which the adjusted results remained statistically significant.

Lastly, two adjustment procedures, ie, regression (not reported) and propensity scores, were used and neither showed any major change of treatment effect.

The larger number of patients treated with a CAI could have introduced a channelling bias, ie, the few severe cases would have been treated with the most effective drug. We believe that two major factors would explain this imbalance: (1) two CAIs were marketed (brinzolamide and dorzolamide), as compared to one of the alpha-2 agonists (brimonidine), and (2) dorzolamide market authorization and access preceded brimonidine by 1 year.

The number of drugs following CAI or alpha-2 agonist treatment failure was somewhat greater after the alpha-2 agonists, suggesting a more frequent occurrence of severe cases in the latter patient group. From a strict standpoint, treatment group imbalance should be considered at the initiation of treatments. Therefore, we did not regard subsequent events as factors influencing treatment persistence. Also, the initiation of a rescue treatment depends on the previous treatment and the choice should take into account the

Table 2 Eye and general comorbidities – UK GPRD prevalence rates

| Comorbidity | Alpha-2 agonists | CAIs | p-value |
|-------------|------------------|------|--------|
| **Ocular comorbidity** | | | |
| Anterior eye structural changes | 273 (19.7%) | 1,015 (21.2%) | 0.2403 |
| Congenital eye disorders | 10 (0.7%) | 36 (0.8%) | 0.9129 |
| Ocular infections, irritations and inflammations | 444 (32.1%) | 1,459 (30.4%) | 0.2461 |
| Ocular injuries | 20 (1.4%) | 66 (1.4%) | 0.8496 |
| Ocular neuro-muscular disorders | 14 (1.0%) | 55 (1.1%) | 0.6711 |
| Ocular sensory symptoms | 12 (0.9%) | 15 (0.3%) | 0.0059 |
| Retina, choroid and vitreous hemorrhages and vascular disorders | 101 (7.3%) | 319 (6.7%) | 0.4043 |
| Ocular hemorrhages and vascular disorders | 64 (4.6%) | 177 (3.7%) | 0.1153 |
| Vision disorders | 262 (18.9%) | 884 (18.4%) | 0.6838 |
| **General comorbidity** | | | |
| Blood and lymphatic disorders | 162 (11.7%) | 618 (12.9%) | 0.2399 |
| Cardiac disorders | 698 (50.4%) | 2,184 (45.6%) | 0.0014 |
| Congenital and genetic disorders | 73 (5.3%) | 279 (5.8%) | 0.4389 |
| Ear disorders | 645 (46.6%) | 2,224 (46.4%) | 0.8989 |
| Endocrine disorders | 289 (20.7%) | 978 (20.4%) | 0.7900 |
| Gastrointestinal | 912 (65.9%) | 3,102 (66.4%) | 0.7256 |
| Liver disorder | 69 (5.0%) | 228 (4.8%) | 0.7274 |
| Immune system disorders | 700 (50.6%) | 2,182 (45.5%) | <0.001 |
| Infections | 1,036 (74.9%) | 3,524 (73.5%) | 0.3264 |
| Injuries | 630 (45.5%) | 2,144 (44.7%) | 0.6078 |
| Metabolism and nutrition disorders | 633 (45.7%) | 2,212 (46.2%) | 0.7808 |
| Musculo-skeletal disorders | 1,083 (78.3%) | 3,722 (77.7%) | 0.6472 |
| Neoplasms benign and malignant | 477 (34.5%) | 1,709 (35.7%) | 0.4116 |
| Nervous system disorders | 892 (64.5%) | 2,898 (60.5%) | 0.0075 |
| Psychiatric disorders | 547 (39.5%) | 2,038 (42.5%) | 0.0458 |
| Renal and urinary disorders | 543 (39.2%) | 1,879 (39.2%) | 0.9877 |
| Respiratory disorders | 1,079 (78.0%) | 3,570 (74.5%) | 0.0085 |
| Skin and subcutaneous tissue disorders | 932 (67.3%) | 3,212 (67.0%) | 0.8274 |

Abbreviation: CAIs, carbonic anhydrase inhibitors.
pharmacodynamics of the drugs concerned, which differ between CAIs and alpha-2 agonists. Lastly, the number of patients given surgery or laser therapy as rescue treatments, ie, the most severe cases, was similar.

Data management was performed ‘blind’, before any patient was selected, with respect to the general glaucoma database where all types of treatment were pooled together. This allowed us to minimize bias when comparing treatments. Also, this approach was meaningful as the compared glaucoma drugs were homogenously distributed, hence choices made at a global level should not have impacted on any specific treatment. We performed sensitivity analyses on subsets of the entire glaucoma database (eg, when selecting the 100-day threshold) because our data management

programs required intensive computer resources (some files exceeded 15 millions lines). Accordingly, we believe that our data management was fair and did not systematically bias treatment comparisons.

Treatment failure was signaled by a change of treatment, ie, adding, stopping or replacing glaucoma medication, surgery or laser therapy, as is common practice with glaucoma analyses of claim data (Deschaseaux-Voinet et al 2003; Nordstrom et al 2005; Covert and Robin 2006; Wilensky et al 2006).

We found a significantly lower rate of treatment failure with CAIs + PGAs over a 4 year period, according to our outcome definition. The comparison between treatment persistence and clinical efficacy is not straightforward since the former encompasses several dimensions which are usually controlled in clinical trials (eg, treatment delivery, compliance, efficacy, safety). Our results could be compared to those of Feldman et al (2007) and Reis et al (2006), who reported randomized, masked studies, comparing dorzolamide and brimonidine. Both sets of authors concluded that the treatments produced equivalent IOP control. Our different observation may be explained by several factors. First, we studied treatments in contrast to the two randomized trials, which concerned second-line treatments. Second, our study

| Duration of treatment | Alpha-2 agonists | CAIs |
|-----------------------|-----------------|------|
| 12 months             | 34.0%           | 41.2%|
| 24 months             | 16.4%           | 22.6%|
| 36 months             | 8.1%            | 12.7%|
| 48 months             | 3.5%            | 6.3% |
| Time to 50% failure incidence rate (month) | 6.5 | 8.5 |

Abbreviation: CAIs, carbonic anhydrase inhibitors.

Figure 1 Time to failure of carbonic anhydrase inhibitors (CAIs) and alpha-2 agonists from the initiation of therapy.
involved large patient populations recorded in the UK-GPRD which provided greater power to observe small significant differences. Third, treatment acceptability may play a role. Although Stewart et al found both treatments to be well tolerated and without significant effects on safety parameters (Stewart et al 2000), Whitson et al (2004) observed significantly more stinging and burning with dorzolamide (CAI) \( (p < 0.02) \) and more frequent dry eyes with brimonidine (alpha-2 agonist) \( (p = 0.04) \) (Whiston et al 2004). Accordingly, in everyday practice it is possible that treatment failure may be related to unwanted effects that patients will not tolerate. Specific patient chart data should be collected to test this hypothesis.

The costs of CAI + PGA were higher than the ones of alpha-2 + PGA while the cost of one bottle of brimonidine was higher (about +20%) than the average cost of the two CAIs participating in the analysis. This was explained by the longer treatment persistence of CAIs. Treatment failure leads to higher costs (Denis et al 2004) as confirmed, here, by the nature of the rescue treatment which in most cases comprised the more costly prostaglandin analogues. Conversely, medications that would lower the failure rate should reduce the costs of patients who receive them. The annual failure rate with CAIs was significantly lower over 4 years than for alpha-2 agonists. Hence, by delaying the need for more expensive glaucoma treatments, CAIs would eventually become less expensive than alpha-2 agonists. Results for adjusted and non-adjusted costs were presented because the follow-up time for patients given CAIs was longer than with alpha-2 agonists. Cost differences during either drug regimen remained non-significant both with and without adjustment.

Second, reasons for modifying treatments are not documented in the UK-GPRD, and that limits a definitive understanding. Given this circumstance, it was assumed that treatment changes were made for reasons of tolerance or lack of efficacy.

### Table 4 Resource utilization after CAI alpha-2 agonist treatment failure

| Rescue treatment | Alpha-2 agonists \( n = 1,319 \) | CAIs \( n = 4,415 \) | Total \( n = 5,734 \) |
|------------------|---------------------------------|-----------------|-----------------|
| Number of drugs | No drugs, 39 (3.0%) | 126 (2.9%) | 165 (2.9%) |
|                  | Monotherapy, 854 (64.7%) | 3,280 (74.3%) | 4,134 (72.1%) |
|                  | 2 drugs, 197 (14.9%) | 435 (9.9%) | 632 (11.0%) |
|                  | 3 drugs, 223 (16.9%) | 553 (12.5%) | 776 (13.5%) |
|                  | 4 drugs, 6 (0.5%) | 21 (0.5%) | 27 (0.5%) |
| Surgery | 32 (2.4%) | 110 (2.5%) | 142 (2.5%) |
| Laser therapy | 7 (0.5%) | 16 (0.3%) | 23 (0.4%) |
| Drug classes | Beta-blocker, 270 (20.5%) | 1,529 (34.6%) | 1,799 (31.4%) |
|                  | Prostaglandin analogue, 845 (64.1%) | 2,732 (61.9%) | 3,577 (62.4%) |
|                  | Alpha-2, 663 (50.3%) | 345 (7.8%) | 1,008 (17.6%) |
|                  | CAI, 249 (18.9%) | 227 (5.1%) | 476 (8.3%) |

**Abbreviation:** CAIs, carbonic anhydrase inhibitors.

### Table 5 Annual average cost of glaucoma according to the treatment (£: 2005)

| Cost item | Alpha-2 agonists | CAIs | p-value |
|-----------|------------------|------|---------|
| Annual total costs from inclusion | 413.83 (700.37) | 421.11 (762.14) | 0.7501 |
| Monthly total costs from inclusion | 34.01 (57.56) | 34.61 (62.64) | 0.7501 |
| Drugs | 23.83 (36.91) | 24.44 (36.93) | ~1 |
| Monthly costs of drugs of study | 7.29 (15.21) | 9.19 (14.55) | <0.0001 |
| Monthly costs of other drugs | 16.54 (22.36) | 15.25 (23.24) | 0.0657 |
| Monthly costs of consultation | 8.01 (19.45) | 8.30 (20.11) | 0.6242 |
| Monthly costs of hospitalization-surgery-laser therapy | 2.17 (16.12) | 1.88 (24.66) | ~1 |
| **Mean daily costs unadjusted** | **1.13 (1.92)** | **1.15 (2.09)** | **0.7501** |
| **Annual adjusted total costs** | **440.63** | **413.37** | **0.2327** |

**Note:** (sd) [CI 95%]

**Abbreviation:** CAIs, carbonic anhydrase inhibitors.
Third, the main limitation of this study was its retrospective design, which precluded any verification of data accuracy. Conversely, we were able to exploit aspects of UK National Health Service regulations that restrict a patient’s access to other physicians, provide longitudinal data, and ensure a high standard of documentation which does not always apply to other health organizations. Hence, we were able to document previous treatments and check group comparability accurately, even though the internal validity of our survey was not equal to that of a randomized clinical trial.

**Conclusion**
According to the UK-GPRD information, glaucoma treatment with CAIs + PGAs was more persistent in everyday practice than alpha-2 agonists + PGAs. Patients continued longer with CAIs. During 4 years of treatment the daily costs of a patient receiving CAIs were similar to those of alpha-2 agonists.

**Acknowledgments**
This analysis was supported by an unrestricted grant from Alcon France SA, Rueil-Malmaison, France. The analysis was performed by Cenika Eval, Bourg-la-Reine, France. Dr Gilles Berdeaux is employed by Alcon France. We would like to thank Robert Pigache MD, FFPM for reviewing the English language.

**References**
Broman AT, Quigley HA. 2006. The number of people with glaucoma worldwide in 2010 and 2020. *Br J Ophthalmol*, 90:253–4.

Bunce C, Wormald R. 2006. Leading causes of certification for blindness and partial sight in England and Wales. *BMJ Public Health*, 6:58.

Concato J, Shah N, Horwitz RI. 2000. Randomized, controlled trials, observational studies, and the hierarchy of research designs. *N Engl J Med*, 342:1887–92.

Covert D, Robin AL. 2006. Adjunctive glaucoma therapy used associated with travoprost, bimatoprost, and latanoprost. *Curr Med Res Opin*, 22:971–6.

Coyle D, Drummond M. 1995. The economic burden of glaucoma in the UK. The need for a far-sighted policy. *PharmacoEconomics*, 7:484–9.

Curtis L, Netten A. Units costs of health and social care 2005 PSSRU University of Kent. (http://www.pssru.ac.uk/)

Denis et al. 2004. Medical predictive factors of glaucoma treatment costs. *J Glaucoma*, 13:283–90.

Deschaseaux-Voinet C, Lafuma A, Berdeaux G. 2003. Cost and effectiveness of brinzolamide versus dorzolamide in current practice: an analysis based on the UK-GPRD data base. *J Med Econ*, 6:69–78.

Dunn D, Babiker A, Hooker M, Darbyshire J. 2002. The dangers of inferring treatment effects from observational data: a case study in HIV infection. *Control Clin Trials*, 23:106–10.

European Medicines Agency. European Public Assessment Report (EPAR). http://www.emea.europa.eu/htms/human/epar/a.htm

Feldman RM, Tanna AP, Gross RL, et al; Additivity Study Group. 2007. Comparison of the ocular hypotensive efficacy of adjunctive brimonidine 0.15% or brinzolamide 1% in combination with travoprost 0.004%. *Ophthalmology*, 114:1248–54.
Vidal. 2006. Edition du Vidal. Paris, France.
Vold SD, Riggs WL, Jackimiec J. 2002. Cost analysis of glaucoma medica-
tions: a 3-year review. J Glaucoma, 11:354–8.
Weih LM, Nanjan M, McCarty CA, et al. 2001. Prevalence and predictors
of open-angle glaucoma: results from the visual impairment project.
Ophthalmology, 108:1966–72.
Whitson JT, Henry C, Hughes B et al. 2004. Comparison of the safety and
efficacy of dorzolamide 2% and brimonidine 0.2% in patients with
glaucoma or ocular hypertension. J Glaucoma, 13:168–73.
Wilensky J, Fiscella RG, Carlson AM, et al. 2006. Measurement of
persistence and adherence to regimens of IOP-lowering glaucoma
medications using pharmacy claims data. Am J Ophthalmol, 141(1
Suppl):S28–33.
Yue LQ. 2007. Statistical and regulatory issues with the application of pro-
pensity score analysis to nonrandomized medical device clinical studies.
J Biopharm Stat, 17:1–13; discussion 15–7, 19–21, 23–7 passim.
